Evaluating the Totality of Evidence

Content Outline

Local RT With ADT for Advanced Prostate Cancer Intergroup Study Final Results

Confirming the Benefit of RT

Local Therapy for Nonmetastatic Prostate Cancer -- STAMPEDE Data

STAMPEDE Outcomes by Tumor Volume in Metastatic Prostate Cancer

New Questions for Optimal Local Therapy

Using Docetaxel for mHSPC Insights from CHAARTED

Docetaxel: High-Volume Disease CHAARTED Primary Analysis

Docetaxel: High- vs Low-Volume Disease CHAARTED Primary Analysis

CHAARTED Final Analysis Low-Volume Disease

PUNCH Trial -- Chemotherapy in the Neoadjuvant Setting

LATITUDE The Role of Frontline Abiraterone in High-Risk mHSPC

Final LATITUDE Results

Abiraterone in Low-Risk/Low-Volume Disease

Should Low-Risk Patients Get Additional Systemic Therapy?

High-Risk Patients Abiraterone or Docetaxel?

Selecting Optimal Add-On Therapy to ADT

Nonmetastatic CRPC

AR-Targeted Therapy for Nonmetastatic CRPC

Earlier Treatment = Longer Time to Progression and Resistance

Toxicity Profiles of Anti-AR Therapies

Feasibility of Sequencing AR Therapies and Anti-Androgen Therapy

Key Questions When Patients Progress to Metastatic Disease

Recent Data in Radiopharmaceuticals

VISION Trial PSMA-Targeted Therapy for mCRPC

Concluding Remarks

Abbreviations

Abbreviations (cont)